Inhibrx Biosciences, Inc. - Common Stock (NQ:INBX)

96.99 -0.94 (-0.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Inhibrx Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying ↗

September 03, 2024

Via Benzinga

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying ↗

August 27, 2024

Via Benzinga

INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024 ↗

August 22, 2024

INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024 ↗

August 14, 2024

INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Top 4 Health Care Stocks That Are Preparing To Pump This Month ↗

June 05, 2024

Via Benzinga

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

May 09, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know ↗

August 23, 2023

Via Benzinga

The NVDA Earnings Effect And What It Means For The Current Market Momentum ↗

February 28, 2024

Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of.

Via Talk Markets

Topics Stocks

Is The Stock Market Ready To Plunge? The Warning Signs Are Here... ↗

February 21, 2024

Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.

Via Talk Markets

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

February 10, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx ↗

January 23, 2024

The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.

Via Investor's Business Daily

Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients ↗

April 26, 2023

Via Benzinga

Why Is Inhibrx (INBX) Stock Soaring 45% Today? ↗

October 04, 2022

Inhibrx received a vote of confidence from the Food and Drug Administration, skyrocketing the largely speculative INBX stock.

Via InvestorPlace

INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders

January 23, 2024

From Halper Sadeh LLC

Via Business Wire

French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B ↗

January 23, 2024

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected...

Via Benzinga

Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project ↗

January 23, 2024

Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.

Via Benzinga

$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying ↗

August 31, 2023

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 29, 2023

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.

Via Benzinga

Topics Intellectual Property

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday ↗

August 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating ↗

May 03, 2023

On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.

Via Investor's Business Daily

Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate ↗

November 16, 2022

Via Benzinga

$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying ↗

October 13, 2022

Although US stocks closed slightly lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Stocks Reverse Gains After ADP Report ↗

October 05, 2022

Wall Street's rally has come to a screeching halt, as Treasury yields tick higher once again.

Via Talk Markets

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗

November 18, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

Via Benzinga

S&P 500 Rises 100 Points; Nasdaq Up 3% ↗

October 04, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.

Via Benzinga

R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

October 05, 2022

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

Via FinancialNewsMedia

Topics Death

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 04, 2022

Gainers

Via Benzinga

Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗

October 04, 2022

Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.

Via Benzinga

Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗

October 04, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.

Via Benzinga

US Stocks Open Higher As Dow Jumps 550 Points ↗

October 04, 2022

U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.